The PMI Atlanta Healthcare Forum has 9 planned sessions throughout 2017. Proposed topics include IT & IT PMO in Healthcare, Healthcare SME/Domain Forums such as Clinical, Laboratory, Research, Tomorrow's Healthcare & Government practices/law, Thought Leadership in Healthcare, and Innovation in Healthcare Technology.
Breast cancer is the second leading cause of cancer-related deaths among women. Majority of young women with BRCA1 mutations have a so-called triple negative breast cancer (TNBC) with an aggressive phenotype. Currently there is no targeted therapy for TNBC. Work ongoing in the lab is geared towards understanding the molecular mechanism of BRCA1 dysfunction in these cancers. We are studying the biological functions of BRCA1 and its disease associated mutant proteins so as to identify the driver mutations that lead to these aggressive cancers.
This work as led to the discovery of a BRCA1 function based assay Patent 8,372,580 the only one in the world that can stratify risk for Triple Negative Breast Cancer development and can be used to develop drugs for targeted therapy of Triple Negative Breast Cancer, a disease which currently has no targeted treatments available.
Dr. Veena N. Rao is Professor and Co-Director of the Cancer Biology Program in the Department of OB/GYN at Morehouse School of Medicine. She was awarded the Georgia Cancer Coalition Distinguished Cancer Scholar Award from the Governor of Georgia for outstanding cancer research. She received her Ph.D. in Biochemistry from Osmania University, India and some of the work was done at Max Planck Institute in Germany, University of Edinburgh, Scotland and MIT, Boston. Her postdoctoral work was from the University of California, Berkeley and Yale University School of Medicine. She was a Forgarty International fellow at National Cancer Institute where she and Dr. Reddy identified the ERG gene (Science 1987) which is involved in prostate cancers. Dr. Rao has a long career beginning at Temple University and then at Thomas Jefferson University in Philadelphia as an Assistant Professor where her group cloned the ELK-1 gene (Science 1989, Nature 1991). Recently Elk-1 was found to play a role in neurodegeneration and schizophrenia. She then moved to Thomas Jefferson University as Associate Professor where she identified and cloned the BRCA1 isoforms.
Dr. Rao has been working in the BRCA1 field since the cloning of the gene in 1994 and has spearheaded numerous breakthroughs in breast and ovarian cancer research. She then moved as Professor and Co-Director of the Division of Cancer Genetics at Allegheny University of the Health Sciences, Philadelphia and then became Professor and Co-Director of the Division of Cancer Genetics at Drexel University. This led her to be recruited as the State of Georgia Cancer Coalition Distinguished Cancer Scholar at Morehouse School of Medicine to initiate a Cancer Biology program at Grady Cancer Center, Grady Memorial Hospital which is a satellite site of Morehouse School of Medicine. She was the research advisor for the first MD, PhD student at Morehouse school of Medicine. Dr. Rao has won numerous awards including outstanding mentor award, MSCR class of 2017. Her work has recently led to discovering a BRCA1 function-based assay, Patent 8,372,580 the only one in the world that can stratify risk for Triple Negative Breast Cancer development and to develop drugs for targeted therapy of Triple Negative Breast Cancer, a disease which currently has no targeted treatments available.
Wednesday, october 18, 2017, 6:00 PM - 8:00 PM
Philips Healthcare, 13560 Morris Road, PHA University Room, Alpharetta, GA 30004
PMI Atlanta Member: $12.00, Early Bird Rate $10.00 through October 11th
Non-Member: $15.00, Early Bird Rate $13.00 through October 11th
Forums no longer accept cash registrations at the door. Please register in advance or via credit card at the door.
Meeting content, presenter, and location are subject to change. Refunds will not be made for changes in meeting content, presenters, or locations.
Earn 1 PDU
Talent Triangle Category: Strategy & Business Management
|Event Date||10-18-2017 6:00 pm|
|Event End Date||10-18-2017 8:00 pm|
|Cut off date||10-20-2017 11:55 pm|
Written By Alex Blench, PMP, MSAThe May Governance Forum hosted PMI Fellow and Managing Partner of Norman & Normal Consulting, LLC Eric Norman for an engaging discussion about how to create lasting value in a PMO. Eric is a management consultant with 25 years of extensive governance and business process design experience. Overview The traditional PMO frequently seems to be in a position to justify its own existence. During this forum, Eric examined why so many PMOs seem to dissolve after just a few...
Get ready. Genomic data and precision medicine are redefining the point of care. Wrriten by Claudia Greene Bud Zborowski, Healthcare Executive, delivered a captivating presentation to the May PMI Atlanta Healthcare Forum. Attendees enjoyed an insightful and informative presentation and discussion on the evolution of Healthcare through Genomics and Precision Medicine at the point of care.Bud is a healthcare corporate and business development executive. His healthcare career accomplishments are...